Anika Lifts 2026 Profit Outlook And Signs 10-Year Hyvisc Deal, But FDA Rejects Hyalofast
Third-quarter revenue rose 10% to $30.6 million as gross margin widened to 62%, while the FDA found Hyalofast not approvable.
Anika Therapeutics, which makes hyaluronic acid products for orthopedic care, raised its 2026 profit forecast after third-quarter revenue rose 10% to $30.6 million, and signed a new 10-year Hyvisc deal with Boehringer Ingelheim. The same report confirmed that the FDA told the company in October that its Hyalofast application is not approvable.
Margin jumps, guidance moves
Revenue compared with $27.8 million a year earlier, the company said in an 8-K filed Friday. Commercial Channel sales were $14.0 million, up about 17%, and OEM Channel sales were $16.6 million, up about 5%. Integrity, the tendon-repair scaffold, grew more than 30% from a year earlier.
Gross margin was 62%, against 56% a year ago, which Anika credited to manufacturing productivity, partly offset by product mix from reintroducing the Hyalomatrix wound product. Adjusted EBITDA was $5.1 million, and adjusted net income from continuing operations was $3.9 million, or $0.29 per share. Standard accounting still showed a loss from continuing operations of $0.3 million, or $0.02 per share.
For 2026, Anika now expects adjusted EBITDA margin of 15% to 17%, from 13% to 17% before, and total revenue growth of 6% to 10%, from 5% to 10%. It cut Commercial Channel growth guidance to 9% to 13% from 12% to 18%, citing a slower elective surgery market, and raised OEM Channel guidance to 5% to 9% from 0% to 5%.
A Hyvisc renewal, and a Hyalofast setback
The new Boehringer Ingelheim agreement, signed in November with an existing partner, brings higher transfer pricing, a royalty on end-market sales and higher contractual purchases. Anika expects $8 million in payments: $4 million upfront in the first quarter of 2027 and $4 million tied to commercial volumes.
The FDA's October notice said the Hyalofast premarket approval application is not approvable, primarily because of the clinical data submitted. Anika said it still believes in the product's U.S. potential and is talking with the agency about what additional evidence a future approval might need.
Cingal enrollment in a bioequivalence study finished in September, and the company expects to file a new drug application before year-end 2027.
Cash, stock pay and the call
Cash stood at $45.0 million on September 30. Stock-based compensation for the first nine months was $12.7 million, up from $7.6 million a year earlier, according to the cash flow statement. Anika also spent $9.5 million repurchasing stock in that period.
Chief Executive Steve Griffin said the results "reinforces our confidence in our full-year 2026 outlook and our 2027 revenue expectations." Management holds a call at 8:30 a.m. ET on Friday.
The company's 2027 guidance calls for total revenue growth of flat to 5%, with Commercial Channel growth of 5% to 15%.
Sources
- 8-K Filing — Anika Therapeutics, Inc. (ANIK) — SEC EDGAR
- Exhibit exh_991.htm — Anika Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates — Yahoo Finance
- Anika Reports Third Quarter 2026 Financial Results — globenewswire.com